Arterial and venous pharmacokinetics of morphine-6-glucuronide and impact of sample site on pharmacodynamic parameter estimates
- PMID: 20547824
- DOI: 10.1213/ANE.0b013e3181e5e8af
Arterial and venous pharmacokinetics of morphine-6-glucuronide and impact of sample site on pharmacodynamic parameter estimates
Abstract
Background: In pharmacokinetic-pharmacodynamic modeling studies, venous plasma samples are sometimes used to derive pharmacodynamic model parameters. In the current study the extent of arteriovenous concentration differences of morphine-6-glucuronide (M6G) was quantified. We used simulation studies to estimate possible biases in pharmacodynamic model parameters when linking venous versus arterial concentrations to effect.
Methods: Seventeen healthy volunteers received an IV 90-second infusion of 0.3 mg/kg morphine-6-glucuronide (M6G). Arterial and venous blood samples, from the radial artery and cubital vein, respectively, were obtained. An extended pharmacokinetic model was constructed linking arterial and venous compartments. The extent of bias in pharmacodynamic model parameter estimates was explored in simulation studies with NONMEM, simulating M6G effect using first-order effect-compartment-inhibitory sigmoid E(MAX) models. M6G effect was simulated at various values for the arterial blood-effect-site equilibration half-lifes (t(1/2)k(E0)), ranging from 5 to 240 minutes.
Results: Arteriovenous concentration differences were apparent, with higher arterial plasma concentrations just after infusion, whereas at later times (>60 minutes) venous M6G concentrations exceeded arterial concentrations. The extended pharmacokinetic model adequately described the data and consisted of 3 arterial compartments, 1 central venous compartment, and 1 peripheral venous compartment. The simulation studies revealed large biases in model parameters derived from venous concentration data. The biases were dependent on the value of t(1/2)k(E0). Assuming that the true values of M6G t(1/2)k(E0) range from 120 to 240 minutes (depending on the end point measured), we would have underestimated t(1/2)k(E0) by 30%, whereas the potency parameter would have been overestimated by about 40%, when using venous plasma samples.
Conclusions: Because of large arteriovenous differences in M6G plasma, concentration biases in pharmacodynamic model parameters will occur when linking venous concentration to effect, using a traditional effect-compartment model.
Similar articles
-
Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences.Anesthesiology. 2004 Jan;100(1):120-33. doi: 10.1097/00000542-200401000-00021. Anesthesiology. 2004. PMID: 14695733 Clinical Trial.
-
Pharmacokinetic modeling to predict morphine and morphine-6-glucuronide plasma concentrations in healthy young volunteers.Clin Pharmacol Ther. 2002 Aug;72(2):151-62. doi: 10.1067/mcp.2002.126172. Clin Pharmacol Ther. 2002. PMID: 12189362
-
The transfer half-life of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers.Anesthesiology. 2001 Dec;95(6):1329-38. doi: 10.1097/00000542-200112000-00009. Anesthesiology. 2001. PMID: 11748388 Clinical Trial.
-
Pharmacokinetic-pharmacodynamic modelling of opioids in healthy human volunteers. a minireview.Basic Clin Pharmacol Toxicol. 2012 Mar;110(3):219-26. doi: 10.1111/j.1742-7843.2011.00814.x. Epub 2011 Nov 9. Basic Clin Pharmacol Toxicol. 2012. PMID: 21995512 Review.
-
Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration: a quantitative review of morphine, morphine-6-glucuronide, and morphine-3-glucuronide.Br J Anaesth. 2014 Dec;113(6):935-44. doi: 10.1093/bja/aeu186. Epub 2014 Jul 1. Br J Anaesth. 2014. PMID: 24985077 Review.
Cited by
-
Sampling Site Has a Critical Impact on Physiologically Based Pharmacokinetic Modeling.J Pharmacol Exp Ther. 2020 Jan;372(1):30-45. doi: 10.1124/jpet.119.262154. Epub 2019 Oct 11. J Pharmacol Exp Ther. 2020. PMID: 31604807 Free PMC article.
-
Are Physiologically Based Pharmacokinetic Models Reporting the Right C(max)? Central Venous Versus Peripheral Sampling Site.AAPS J. 2015 Sep;17(5):1268-79. doi: 10.1208/s12248-015-9796-7. Epub 2015 Jun 23. AAPS J. 2015. PMID: 26100012 Free PMC article.
-
Safety, pharmacokinetic and pharmacodynamic properties of single ascending dose and continuous infusion of remimazolam besylate in healthy Chinese volunteers.Eur J Clin Pharmacol. 2020 Mar;76(3):383-391. doi: 10.1007/s00228-019-02800-3. Epub 2019 Dec 23. Eur J Clin Pharmacol. 2020. PMID: 31873765 Clinical Trial.
-
Clinical Pharmacokinetics and Pharmacodynamics of Naloxone.Clin Pharmacokinet. 2024 Apr;63(4):397-422. doi: 10.1007/s40262-024-01355-6. Epub 2024 Mar 14. Clin Pharmacokinet. 2024. PMID: 38485851 Free PMC article. Review.
-
Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers.Anesthesiology. 2012 Aug;117(2):353-64. doi: 10.1097/ALN.0b013e31825b6c91. Anesthesiology. 2012. PMID: 22692377 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources